TG4050 is a neoantigenic cancer vaccine derived from Transgene's myvac platform and leverages NEC's Artificial Intelligence (AI) technologies to identify and predict the most potent neoantigens for immunogenicity. According to the data presented at the AACR 2024 conference, at a median follow-up duration of 18.6 months, all assessable patients who received the vaccine following standard-of-care adjuvant chemoradiotherapy (n = 16; arm A) remained in remission. Among those placed in the observation group (n = 16; arm B), three individuals encountered disease recurrence at 6.2, 8.8, and 18.5 months, respectively. Additionally, immune responses were assessed in 16 vaccina...
